Foundation Fighting Blindness VISIONS 2018 is the Leading Global Conference Showcasing Advances in Retinal Research

The Foundation Fighting Blindness VISIONS 2018 conference, June 21 – 23, 2018 at the Sheraton San Diego Hotel and Marina, will bring together the world’s leading vision scientists, assistive technologies experts, and the visually impaired community.

Watch VISIONS 2018 LIVE on June 22 & 23

Get the inside scoop on this year’s top research advances and what’s next in retinal disease science by watching VISIONS 2018 LIVE!
We will be streaming several of our annual VISIONS conference sessions live on Friday, June 22 and Saturday, June 23. The sessions will be live streamed here on our blog, and our national Facebook as well.
Here’s the full schedule of live sessions:
Friday, June 22, 2018

Foundation Fighting Blindness Clinical Research Institute Hosted Workshop for ProgStar, the Largest Natural History Study for Stargardt Disease Ever Launched

The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development

Columbia, MD – More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) in 2013.

Foundation Fighting Blindness and CheckedUp® Partner to Educate Retinal-Disease Patients About Research, Resources, and Emerging Therapies During Doctor Visits

CheckedUp multimedia system will provide targeted disease and research information to retinal-disease patients in waiting and exam rooms at 1,000 ophthalmology practices in US.

French Gene Therapy Company Advancing Three Programs for Retinal Diseases

Audio version:
Horama, a French biotech developing gene therapies for rare eye diseases, was established in 2014 as a spin-off of INSERM, France’s public scientific and technology institute. Today, the company has three gene-therapy development programs underway for rare inherited retinal diseases, targeting people with mutations in the genes PDE6B, RPE65, and RLBP1.

ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD

Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.